Therapix Biosciences (NASDAQ:TRPX) reported topline results from its Phase 2a clinical study of THX-110 for the treatment of obstructive sleep apnea (OSA).
THX-110 is a combination of dronabinol, or synthetic THC, and CannAmide, an immediate release formulation of the cannabimimetic compound palmitoylethanolamide. Cannamide was approved by Health Canada in July 2019.
Each of 10 subjects received one daily treatment of oral THX-110 for 30 days. Doses were titrated, with a maximum THX-110 dose of 10 mg dronabinol and 800 mg PEA. Of the nine patients that completed the study, 55% demonstrated significant improvement in apnea–hypopnea index values.
“OSA is a medical disorder that affects about 10% of the adult population with significant medical consequences, such as hypertension, ischemic heart disease and sleepiness, which can lead to road and work accidents,” professor Yaron Dagan, head of the Sleep Medicine Institute at Assuta, said in a statement.
“The main treatment available is using a continuous positive airway pressure device every night, which has a very low compliance. This pioneering study of a successful medical treatment is very promising,” he added.